HTHSCI 2H03 Lecture Notes - Lecture 7: Anti-Diabetic Medication, Hypokalemia, Thiazide
24 May 2016
School
Department
Course
Professor
Document Summary
Indications (disease state) primary, secondary and tertiary. First line therapy for the treatment of htn. Reduce blood volume by increasing urinary excretion of sodium. Block sodium/chloride transporter in the distal tubule, facilitating the urinary excretion of sodium and chloride. Potassium sparing diuretic, or potassium rich diet. Dehydration make sure client knows to look for this. Must be cautious of hypokalemia drugs pull out potassium. Use caution in: severe renal disease, gout (increased uric acid) liver disease, hyperlipidemia. Monitor: sodium and potassium levels, kidney function, and blood pressure within 4-6 weeks of starting therapy (risk of hypotension) Should be taken on an empty stomach improves absorption. Increase production of vasodilatory kinins open up vasculature. Do not combine with potassium- sparing diuretic cause hyperkalemia because it causes potassium uptake. Decreased antihypertensive activity with nsaids (chronic use) First dose phenomenon: sudden drop in bp, tachycardia suggested they do not drive.
